We validated a clinical bait-capture WTS assay using 78 solid tumor samples across diverse tissue types, including 59 with known fusions or oncogenic splice variants. Sensitivity was assessed against ...
The Caris Lookback Program identified 13,293 patients potentially eligible for newly approved targeted therapies across 10 ...
Introducing a new RNA-seq platform for intracellular multimodal profiling that could transform cancer research and ...
Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Cancer Immunology, Immunotherapy ...
Genetic variants that cause rare disorders may remain elusive even after expansive testing, such as exome sequencing. The diagnostic yield of genome sequencing, particularly after a negative ...
This image illustrates the typical steps in next-generation sequencing (excluding single-molecule sequencing methods). The process begins with isolating genomic DNA (a) and breaking it into short ...
Researchers have introduced a novel diagnostics method that can more sensitively detect gene fusions in B-cell acute ...
Caris Life Sciences submits application to NYSDOH Clinical Laboratory Evaluation Programme for Caris Assure blood based testing authorization: Irving, Texas Monday, May 11, 2026, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results